US HIV/AIDS program hit target early

8 December 2008

The US President's Emergency Plan for AIDS Relief (PEPFAR) has reached its target of providing treatment to two million people worldwide by the end of 2008, with over three months to spare. The scheme was launched in 2004 by President George W Bush with the aim of making a dramatic impact on the number of HIV/AIDS patients who receive antiretroviral drugs. At the time, despite years of efforts from the World Health Organization and other groups, only 50,000 people in sub-Saharan Africa had access to ARVs. The PEPFAR has raised that figure beyond two million.

In July this year, the program was amended to drop an earlier requirement that one third of funds be spent on sexual abstinence promotion, while the budget was raised from $15.0 billion to $48.0 billion per year.

Another area of complaint from anti-patent activists has been the insistence that generic ARVs deployed in the PEPFAR must be approved by the US Food and Drug Administration. One counter-argument made by the UK-based development think-tank, the International Policy Network against alternative programs, which are more "generic friendly," is that these have distributed substandard products from India and elsewhere, to meet political targets.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight